Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer

BACKGROUND & OBJECTIVES: An association between over-expression of proto-oncogene Her-2/neu and resistance to tamoxifen in estrogen receptor (ER) positive, primary and metastatic breast cancer has been suggested. HR+/Her-2/neu+ patients have a poor response to endocrine therapy, making this grou...

Descripción completa

Detalles Bibliográficos
Autores principales: James, Rani, Thriveni, K., Krishnamoorthy, Lakshmi, Deshmane, Vijayalaxmi, Bapsy, P.P., Ramaswamy, Girija
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100149/
https://www.ncbi.nlm.nih.gov/pubmed/21321422

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100149/
https://www.ncbi.nlm.nih.gov/pubmed/21321422

Ejemplares similares